Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results

KEY TAKEAWAYSNovo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people achieved weight loss from a mean baseline body weight of 92.7 kg (202.8 pounds) in three different maintenance doses, while those treated with placebo gained weight.Novo Nordisk shares have been trending lower since September on slowing sales and increasing competit ...